Question to the Department of Health and Social Care:

To ask Her Majesty's Government when they estimate that the first plasma derived medicinal products sourced from UK plasma donors will become available for the treatment of NHS patients.

The safety of United Kingdom plasma is reviewed periodically. A comprehensive review of the safety of immunoglobulins produced from fractionated UK plasma was conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) during 2020 and is now under consideration by the Department and the devolved administrations.

The Department will work with the devolved administrations, NHS England and NHS Improvement, the MHRA and NHS Blood and Transplant to consider the implications of any decision on the UK supply of plasma for immunoglobulin.